|Bid||307.01 x 800|
|Ask||306.01 x 800|
|Day's range||307.00 - 328.17|
|52-week range||302.61 - 659.45|
|Beta (5Y monthly)||0.93|
|PE ratio (TTM)||58.18|
|Earnings date||27 Apr 2022 - 02 May 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||546.94|
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of DexCom, Inc...
Let's look at two top stocks that have performed worse than the broader market this year: DexCom (NASDAQ: DXCM) and Microsoft (NASDAQ: MSFT). Shares of medical devices specialist DexCom have dropped by 39% year to date. DexCom's own G6 CGM system continues to be highly successful.
SAN DIEGO, May 10, 2022--DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the following upcoming investor conferences: